References
1. Nair G.B., Niederman M.S. Updates on community acquired pneumonia management in the ICU. Pharm Ther. 2021; 217: 107663. DOI: https://doi.org/10.1016/j.pharmthera.2020.107663
2. Ramirez J.A., Wiemken T.L., Peyrani P., et al. Adults hospitalized with pneumonia in the united states: incidence, epidemiology, and mortality. Clin Infect Dis. 2017; 65 (11): 1806–12. DOI: https://doi.org/10.1093/cid/cix647
3. Bayramova S.S., Nikolaev K. Yu., Tsygankova O.V. The use of a new semi-quantitative rapid test for procalcitonin in the diagnosis of multisegmental community-acquired pneumonia. Terapevticheskiy arkhiv [Therapeutic Archive]. 2021; 93 (3): 279–82. DOI: https://doi.org/10.26442/00403660.2021.03.200654 (in Russian)
4. Kharlamova O.S., Nikolaev K.Y., Ragino Y.I., Voevoda M.I. Association of SP-A and SP-D Surfactant Proteins with the Severity of CommunityAcquired Pneumonia. Neotlozhnaya meditsinskaya pomoshch’. Zhurnal imeni N.V. Sklifosovskogo [Emergency Health Care. The Journal named after N.V. Sklifosovsky]. 2020; 9 (3): 348–55. DOI: https://doi.org/10.23934/2223-9022-2020-9-3-348-355 (in Russian)
5. Metlay J.P., Waterer G.W., Long A.C., Anzueto A., Brozek J., Crothers K., et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019; 200 (7): e45–67. DOI: https://doi.org/10.1164/rccm.201908-1581ST
6. Baysultanova R.E.-P., Rachina S.A., Sukhorukova M.V., et al. Community-acquired pneumonia in persons with diabetes mellitus: epidemiology, etiology, diagnosis, treatment and prevention. Prakticheskaya pul’monoliya [Practical Pulmonology]. 2020; (1): 38–48. URL: https://cyberleninka.ru/article/n/vnebolnichnaya-pnevmoniya-u-lits-s-saharnym-diabetom-epidemiologiya-etiologiya-diagnostika-lechenie-i-profilaktika (date of access January 10, 2022). (in Russian)
7. Tsygankova O.V., Khudyakova A.D., Latyntseva L.D., Lozhkina N.G. Cаrdiovascular continuum: from risk factors to the systolic heart failure (the clinical case). Ateroskleroz [Atherosclerosis]. 2017; 13 (4): 42–6. DOI: https://doi.org/10.15372/ATER-20170407 (in Russian)
8. Cheng S., Hou G., Liu Z., et al. Risk prediction of in-hospital mortality among patients with type 2 diabetes mellitus and concomitant community-acquired pneumonia. Ann Palliat Med. 2020; 9 (5): 3313–25. DOI: https://doi.org/10.21037/apm-20-1489
9. Li S., Wang J., Zhang B., et al. Diabetes mellitus and cause-specific mortality: a population-based study. Diabetes Metab J. 2019; 43 (3): 319–41. DOI: https://doi.org/10.4093/dmj.2018.0060
10. Ito A., Ishida T. Diagnostic markers for community-acquired pneumonia. Ann Transl Med. 2020; 8 (9): 609. DOI: https://doi.org/10.21037/atm.2020.02.182
11. Finch S., Keir H.R., Dicker A.J., et al. The past decade in bench research into pulmonary infectious diseases: what do clinicians need to know? Respirology. 2017; 22: 1062–72. DOI: https://doi.org/10.1111/resp.13106
12. Pantzaris N.D., Spilioti D.X., Psaromyalou A., et al. The use of serum procalcitonin as a diagnostic and prognostic biomarker in chronic obstructive pulmonary disease exacerbations: a literature review update. J Clin Med Res. 2018; 10 (7): 545–51. DOI: https://doi.org/10.14740/jocmr3458w
13. Kolosov V.P., Kochegarova E. Yu., Naryshkina S.V. Community-acquired pneumonia. Clinical course, prediction of outcomes. Blagoveshchensk: FGBU «DNTs FPD» SO RAMN, 2012: 124 p. (in Russian)
14. Eley C.V., Sharma A., Lecky D.M., et al. Qualitative study to explore the views of general practice staff on the use of point-of-care C reactive protein testing for the management of lower respiratory tract infections in routine general practice in England. BMJ Open. 2018; 8 (10): e023925. DOI: https://doi.org/10.1136/bmjopen-2018-023925
15. Veliev S.N., Afinogenova G.N., Gudkova I.A. Test system for immunochromatographic determination of procalcitonin in whole blood, serum or plasma samples for the purpose of rapid diagnosis of sepsis Patent for invention RU 169868 U 1. Application No. 2016117522, dated 04.05.2016. (in Russian)
16. Wang X., Sun Y., Shao X. Predictive value of procalcitonin for infection of patients with type-2 diabetes mellitus. Exp Ther Med. 2019; 18 (1): 722–8. DOI: https://doi.org/10.3892/etm.2019.7611
17. Zakariah N.A., Bajuri M.Y., Hassan R., et al. Is procalcitonin more superior to hs-CRP in the diagnosis of infection in diabetic foot ulcer? Malays J Pathol. 2020; 42 (1): 77–84.
18. Ignatova G.L., Blinova Ye.V., Struch S.V., Syrochkina M.A. Risk of community acquired pneumonia in patients with diabetes mellitus. Terapevticheskiy arkhiv [Therapeutic Archive]. 2022; 94 (3): 448–53. (in Russian)
19. Li F., Kong S., Xie K., et al. High ratio of C-reactive protein/procalcitonin predicts Mycoplasma pneumoniae infection among adults hospitalized with community acquired pneumonia. Scand J Clin Lab Invest. 2021; 81 (1): 65–71. DOI: https://doi.org/10.1080/00365513.2020.1858491
20. Maalmi H., Herder C., Strassburger K., Urner S., Jandeleit-Dahm K., Zaharia O.P., et al. Biomarkers of inflammation and glomerular filtration rate in individuals with recent-onset type 1 and type 2 diabetes. J Clin Endocrinol Metab. 2020; 105 (12): dgaa622. DOI: https://doi.org/10.1210/clinem/dgaa622